Comment on: Feedback to Tolterodine QTMALHOTRA, B. K; GLUE, P.Clinical pharmacology and therapeutics. 2008, Vol 83, Num 2, pp 233-233, issn 0009-9236, 1 p.Article

Thorough QT study with recommended and supratherapeutic doses of tolterodineMALHOTRA, B. K; GLUE, P; SWEENEY, K et al.Clinical pharmacology and therapeutics. 2007, Vol 81, Num 3, pp 377-385, issn 0009-9236, 9 p.Article

Long-acting formulation of a new muscarinic receptor antagonist for the treatment of overactive bladderLESHENG TENG; CHAOJUN JIANG; FENGYING SUN et al.Journal of microencapsulation. 2013, Vol 30, Num 2, pp 116-123, issn 0265-2048, 8 p.Article

Tolterodine for the treatment of urge urinary incontinenceELTERMAN, Dean S; CHUGHTAI, Bilal; KAPLAN, Steven A et al.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 14, pp 1987-1991, issn 1465-6566, 5 p.Article

Comparative adherence to oxybutynin or tolterodine among older patientsGOMES, Tara; JUURLINK, David N; MAMDANI, Muhammad M et al.European journal of clinical pharmacology. 2012, Vol 68, Num 1, pp 97-99, issn 0031-6970, 3 p.Article

LC―MS―MS Separation and Simultaneous Determination of Tolterodine and its Active Metabolite, 5-Hydroxymethyl Tolterodine in Human PlasmaYADAV, Manish; UPADHYAY, Vivek; CHAUHAN, Vipul et al.Chromatographia (Wiesbaden). 2010, Vol 72, Num 3-4, pp 255-264, issn 0009-5893, 10 p.Article

Tolterodine Extended Release With or Without Tamsulosin in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms : Effects of Prostate Size. CommentariesROEHRBORN, Claus G; KAPLAN, Steuen A; JONES, J. Stephen et al.European urology. 2009, Vol 55, Num 2, pp 472-481, issn 0302-2838, 10 p.Article

Tolterodine Treatment Improves Storage Symptoms Suggestive of Overactive Bladder in Men Treated With α-BlockersCHAPPLE, Christopher; HERSCHORN, Sender; ABRAMS, Paul et al.European urology. 2009, Vol 56, Num 3, pp 534-543, issn 0302-2838, 10 p.Article

Urinary Incontinence at Orgasm : Relation to Detrusor Overactivity and Treatment Efficacy. CommentariesSERATI, Maurizio; SALVATORE, Stefano; UCCELLA, Stefano et al.European urology. 2008, Vol 54, Num 4, pp 911-917, issn 0302-2838, 7 p.Article

Design of the behavior enhances drug reduction of incontinence (BE-DRI) studyContemporary clinical trials. 2007, Vol 28, Num 1, pp 48-58, issn 1551-7144, 11 p.Article

Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response testSUZUKI, Masanori; NOGUCHI, Yukiko; OKUTSU, Hiroko et al.European journal of pharmacology. 2007, Vol 557, Num 2-3, pp 154-158, issn 0014-2999, 5 p.Article

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder : A randomized controlled trialKAPLAN, Steven A; ROEHRBORN, Claus G; ROVNER, Eric S et al.JAMA, the journal of the American Medical Association. 2006, Vol 296, Num 19, pp 2319-2328, issn 0098-7484, 10 p.Article

Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturiaKAPLAN, Steven A; ROEHRBORN, Claus G; DMOCHOWSKI, Roger et al.Urology (Ridgewood, NJ). 2006, Vol 68, Num 2, pp 328-332, issn 0090-4295, 5 p.Article

Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasiaKAPLAN, Steven A; WALMSLEY, Konstantin; TE, Alexis E et al.The Journal of urology. 2005, Vol 174, Num 6, pp 2273-2276, issn 0022-5347, 4 p.Article

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladderCHAPPLE, C. R; RECHBERGER, T; AL-SHUKRI, S et al.BJU international (Papier). 2004, Vol 93, Num 3, pp 303-310, issn 1464-4096, 8 p.Article

Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: A randomized, placebo-controlled trial. CommentaryKHULLAR, Vik; HILL, Simon; LAVAL, Karl-Ulrich et al.Urology (Ridgewood, NJ). 2004, Vol 64, Num 2, pp 269-275, issn 0090-4295, 7 p.Article

Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutyninSATHYAN, Gayatri; DMOCHOWSKI, Roger R; APPELL, Rodney A et al.Clinical pharmacokinetics. 2004, Vol 43, Num 14, pp 1059-1068, issn 0312-5963, 10 p.Article

Does gender or age affect the efficacy and safety of tolterodine?MICHEL, Martin C; SCHNEIDER, Tim; KREGE, Susanne et al.The Journal of urology. 2002, Vol 168, Num 3, pp 1027-1031, issn 0022-5347Article

Tolterodine and its active 5-hydroxymethyl metabolite: Pure muscarinic receptor antagonistsNILVEBRANT, Lisbeth.Pharmacology & toxicology. 2002, Vol 90, Num 5, pp 260-267, issn 0901-9928Article

Tolterodine-associated acute mixed liver injurySCHLIENGER, Raymond G; KELLER, Martin J; KRÄHENBÜHL, Stephan et al.The Annals of pharmacotherapy. 2002, Vol 36, Num 5, pp 817-819, issn 1060-0280Article

Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous systemTODOROVA, Anelia; VONDERHEID-GUTH, Betting; DIMPFEL, Wilfried et al.Journal of clinical pharmacology. 2001, Vol 41, Num 6, pp 636-644, issn 0091-2700Article

The overactive bladder in children : a potential future indication for tolterodineHJÄLMAS, K; HELLSTRÖM, A-L; MOGREN, K et al.BJU international (Papier). 2001, Vol 87, Num 6, pp 569-574, issn 1464-4096Conference Paper

Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activityBRYNNE, N; FORSLUND, C; HALLEN, B et al.British journal of clinical pharmacology. 1999, Vol 48, Num 4, pp 564-572, issn 0306-5251Article

Factors involved in the success of antimuscarinic treatmentABRAMS, P; LARSSON, G; CHAPPLE, C et al.British journal of urology. Supplement. 1999, Vol 83, Num 2, pp 42-47, issn 1358-8672Conference Paper

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodineBRYNNE, N; DALEN, P; ALVAN, G et al.Clinical pharmacology and therapeutics. 1998, Vol 63, Num 5, pp 529-539, issn 0009-9236Article